Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
説明 | Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. |
分子量 | 1793.12 |
分子式 | C86H97Cl3N10O26 |
CAS No. | 171099-57-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Oritavancin(LY-333328) 171099-57-3 Others Oritavancin(LY 333328) Oritavancin(LY333328) Inhibitor inhibitor inhibit